In late October, Moderna said the UK's Medicines and Healthcare products Regulatory Agency had begun a " rolling review " of its product, a process designed to fast-track the approval of new medicines. Leading Monday's Downing Street press conference, Hancock announced the deal with Moderna, saying it had been negotiated earlier that day, and that the first doses could be delivered to the UK in spring next year.